←
Hope Rugo4,319 posts
Hope Rugo avatar✓

Hope Rugo ✓

@hoperugo
◷ Joined August 2012▧ 680 Photos and videos
Hope Rugo avatar
Hope Rugo@hoperugo·Nov 16

Exciting news! Today the FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. First approval for giredestrant!! FDA.gov. @OncoAlert @OncBrothers

Paolo Tarantino avatar
⟳ Hope Rugo retweeted
Paolo Tarantino@PTarantinoMD·Nov 10

There was a time when treating HER2+ breast cancer was relatively simple. That time is over. And that’s great news! Not long ago, we recommended TCHP for most patients with stage II–III disease, and THP (CLEOPATRA) for those with metastatic disease. Straightforward. Almost one-size-fits-all. Within just a few years, that simplicity is gone. And that’s progress. More opportunities to spare unnecessary toxicity, tailor treatments to patients’ preferences, and move beyond rigid algorithms. To be more doctors. In early-stage disease, options now range from de-escalated THP to intensified regimens such as DB11. In metastatic disease, T-DXd/P has achieved unprecedented PFS (>3 years in the 1L setting!), with novel maintenance strategies (palbociclib or tucatinib) potentially pushing the bar even higher. Meanwhile, biomarkers are finally coming of age, from imaging to tissue and plasma. What an era to be treating HER2+ breast cancer! But more options also mean more complexity. For oncologists, and especially for patients. More knowledge needed, more discussions, more decisions to make. How do we navigate this increasingly complex landscape and choose the right treatment for the right patient? We tried to offer some guidance in our new review recently published in @NatRevClinOncol. Read it here: nature.com/articles/s41571-0… @ValenzaCarmine

Post attachment
Ashish K. Jha avatar
⟳ Hope Rugo retweeted
Ashish K. Jha@ashishkjha·Nov 8

Happy Diwali from India to all celebrating A time to remember that: Light over darkness 
Understanding over ignorance 
Love over intolerance These are the foundations of a healthier, better world. 🪔

Mali Barbi, MD MSc | Breast & Gyn Oncologist avatar
⟳ Hope Rugo retweeted
Mali Barbi, MD MSc | Breast & Gyn Oncologist@DrBarbiOnc·Nov 6

Almost every week a patient asks me: no mutation, I eat well, I don’t drink, why did I get #BreastCancer ? Most of the time I don’t have a good answer, and I tell her it is not something she did. This week @JCO_ASCO published a Sister Study paper on forever chemicals. Women with higher #PFOS and #PFOA in blood drawn before diagnosis had more ER-negative breast cancer (HR 1.93 and 1.67). It is a signal, not a cause. 17 PFAS were tested and one looked protective. And breastfeeding lowers PFAS levels and ER-negative risk, so I want to see how that was handled. But it reminds me how much we still don’t know about why. Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…

@WECARE BIOPHARMA_WeiHePhD avatar
⟳ Hope Rugo retweeted
@WECARE BIOPHARMA_WeiHePhD@DtrmWeihe·Nov 7

@Nature There are other scientists who also died in the same train accident while attending the #ESMO2026 Annual Conference. It’s the best memorial for their families & friends if @Nature publishes another article about all scientists (& including family members) died. RIP🙏🙏🙏

Yakup Ergün avatar
⟳ Hope Rugo retweeted
Yakup Ergün@dr_yakupergun·Nov 1

Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative Breast Cancer: A Pooled Analysis of the BrighTNess, Cancer and Leukemia Group B 40603 (Alliance), and GeparSixto Clinical Trials ascopubs.org/doi/full/10.120…

Hope Rugo avatar
Hope Rugo@hoperugo·Oct 29

Exciting to see so many presentations in print on the day of presentation. For the first time ever - 6 papers in @ESMO_Open. Congratulations to the authors and thanks to @esmo, our editors, and Elsevier for helping this happen!

Post attachment
Hope Rugo avatar
Hope Rugo@hoperugo·Oct 26

#ESMO26 @PTarantinoMD presents the novel and unique Charisma trial with matched samples starting an ADC then with PD. My take? Resistance is incredibly complex and not due to an isolated pathway. Down reg of receptor target uncommon. @OncoAlert

Post attachment
Hope Rugo avatar
Hope Rugo@hoperugo·Oct 26

#ESMO26 ctDNA response predicted long disease control in mHER2+ disease published today in the open access @ESMO_Open could direct stopping therapy earlier in a subset. STOPHER2 ongoing. @OncoAlert

Post attachment